Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041)

NCT02180061 PHASE1 COMPLETED Results posted

This study will assess the safety, tolerability, and efficacy of every-3-week dosing (Q3W) of pembrolizumab (MK-3475) in participants with advanced melanoma; participants may receive pembrolizumab for up to 2 years if deriving clinical benefit. The primary study hypothesis is that treatment with single agent pembrolizumab will result in a clinically meaningful overall response rate.

Details

Lead sponsor	Merck Sharp & Dohme LLC
Phase	PHASE1
Status	COMPLETED
Enrolment	42
Start date	Tue Jul 15 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Aug 31 2017 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Melanoma

Interventions

• Pembrolizumab